Discontinuing or Tapering Preventive Therapy for Tension-Type Headache
For chronic tension-type headache (TTH), continue successful preventive treatment for 3-6 months, then gradually taper and discontinue the medication while monitoring for recurrence.
Timing of Discontinuation
The evidence supports a specific timeframe for preventive therapy duration:
- Maintain treatment for 3-6 months after achieving therapeutic benefit 1, 2
- This duration allows for adequate assessment of efficacy and stabilization of headache patterns
- The 2024 VA/DoD guideline 3 emphasizes that amitriptyline is the first-choice drug for chronic TTH prevention, and this timeline applies to its use
Tapering Strategy
Gradual dose reduction is essential rather than abrupt cessation:
- Slowly decrease the dose to find the minimum effective dose 4
- Monitor headache frequency during the taper using a headache diary
- If headaches remain controlled at lower doses, continue tapering toward discontinuation
- If symptoms recur during taper, return to the previous effective dose
Key Monitoring Parameters During Taper
Track these specific outcomes:
- Monthly headache days - the primary efficacy measure 5
- Headache intensity and duration
- Functional disability and quality of life impact
- Any trigger factors that may have changed
Common Pitfalls to Avoid
Medication overuse must be ruled out before attributing treatment failure 2:
- Excessive use of acute medications (>2 days per week) can cause medication-overuse headache
- Poor compliance may masquerade as treatment failure
- Address these issues before concluding the preventive therapy is ineffective
When to Restart or Continue Treatment
Consider long-term or repeated courses if:
- Headaches return to previous frequency/severity after discontinuation
- The patient had chronic TTH (≥15 headache days per month) rather than episodic TTH
- Quality of life significantly deteriorates without preventive therapy
Evidence Quality Note
The evidence for specific tapering protocols in TTH is limited. The recommendations are based on expert consensus from guidelines 3, 2 and general principles from prophylactic headache treatment studies 1, 4. Recent network meta-analysis confirms amitriptyline 100 mg as the highest-ranked treatment for reducing monthly headache days in chronic TTH 5, supporting its use as the primary preventive agent to be tapered according to this protocol.